Clinical Trial Update: Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics results for oral ixazomib in participants with advanced nonhematologic malignancies or lymphoma have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• NINLARO (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Nonhematologic Malignancies, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2017-11-01